Stoke Therapeutics Announces New Data Supporting Potential For STK-001 To Be First Disease-Modifying Medicine For Treatment Of Patients With Dravet Syndrome
Portfolio Pulse from Benzinga Newsdesk
Stoke Therapeutics announced promising Phase 1/2a end of study data for STK-001, showing significant reductions in convulsive seizure frequency in Dravet Syndrome patients. The data revealed 85% median reduction at 3 months and 74% at 6 months with 70mg doses. Open label extension studies showed durable seizure reductions and cognitive improvements over 12 months with 30mg and 45mg doses. STK-001 was well-tolerated, and the company plans to discuss registrational study design with regulatory agencies, aiming for initial doses of 70mg followed by 45mg. A webcast for analysts and investors is scheduled for 4:30 p.m. Eastern Time today.
March 25, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stoke Therapeutics' STK-001 shows promising results in reducing seizure frequency in Dravet Syndrome patients, with plans to proceed to registrational study design.
The positive Phase 1/2a data for STK-001 demonstrates substantial efficacy in reducing convulsive seizure frequency in Dravet Syndrome patients, which is a significant milestone for Stoke Therapeutics. The well-tolerated nature of the treatment and the company's plans to discuss the registrational study design with regulatory agencies indicate a strong potential for STK-001 to become the first disease-modifying medicine for Dravet Syndrome. This news is likely to be viewed positively by investors and could lead to increased investor confidence in Stoke Therapeutics, potentially driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100